Pulmonology Lasers Market Segmentation:
Application Segment Analysis
The lung cancer treatment segment of the pulmonology lasers market is projected to hold a dominant 40% revenue share by the end of 2037. The rise is being encouraged by the escalating cases of non-small cell lung cancer (NSCLC), especially in the elderly. This is driving the demand for higher accuracy in pulmonology laser technology. According to the National Cancer Institute, lung cancer remains the second common cancer in the U.S. Laser resection is increasingly becoming an attractive alternative since it is less invasive, particularly in the removal of inoperable tumors. Also, NIH-funded research, under the LungMAP initiative, supports the use of laser-assisted bronchoscopy. This also enables image-guided therapies that are associated with fewer risks in procedures.
End User Segment Analysis
The hospitals segment is poised to account for 47% revenue share in the market due to the integrated infrastructure, availability of trained thoracic surgeons, and Government reimbursement plans. In 2023, coverage of bronchial laser ablation was broadened by the Centers for Medicare & Medicaid Services, making it more widely used in tertiary care hospitals. Also, the indirect stimulus to capital investments in pulmonology laser equipment in hospitals comes in the form of federal funding of the lung health programs, namely, the CDC National Asthma Control Program.
Our in-depth analysis of the pulmonology lasers market includes the following segments:
|
Segment |
Subsegments |
|
Type |
|
|
Application |
|
|
End User |
|
|
Technology |
|
